Tumor composite antigen, dendritic cell multivalent vaccine and application of dendritic cell multivalent vaccine

Abstract

The invention discloses a tumor composite antigen, a dendritic cell multivalent vaccine and application of the tumor composite antigen and the dendritic cell multivalent vaccine. Dendritic cells of a patient are stimulated in vitro, multiple tumor cell lysates with super immunogenicity aiming at different EBV related tumors are loaded, mature dendritic cells are formed under induction of multiple cell factors and specific agonists, a complete DC vaccine with corresponding cancer antigens is formed, the DC vaccine is transfused back to a human body to activate an immune system, and the EBV related tumors are subjected to tumor immunogenicity. Natural immunity (such as induction of NK cells) is stimulated, lymphocytes are stimulated to generate acquired immune response, cytotoxic T cells are generated to kill cancer cells, and the cancer cells are accurately killed together; compared with radiotherapy and chemotherapy, the composition is particularly safe and almost has no side effect; and the dendritic cell vaccine has a preparation cycle of about 1 week, and is short in time and low in cost.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a tumor compound antigen, dendritic cell multivalent vaccine and application thereof. Background technique [0002] Epstein-Barr virus (EBV) is a member of the genus Lymphotropia in the family Herpesviridae, and its genome is DNA with a length of about 170kb. The population is generally susceptible, and it spreads widely all over the world. The infection rate of adults is as high as 95%. The virus can be carried for life, and the resulting disease has regional differences. EBV infection mostly occurs in childhood and adolescence. After infecting the body, some cases develop into long-term latent infection, but it may also lead to the formation of various human malignant tumors, such as Burkitts lymphoma (BL), nasopharyngeal carcinoma (NPC) , Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), gastric cancer, breast cancer, and tumors in patients with immunodeficiency. In addi...

AI Technical Summary

Problems solved by technology

[0012] Defects and insufficiencies of the existing technology: Due to the difficulty in early detection of EBV-related tumors such as nasopharyngeal carcinoma and gastric cancer, traditional treatment is still the main treatment in the middle and late stages, and the inhibition rate of traditional surgery, radiotherapy and chemotherapy on tumor cells is about 20%. The inhibition rate of lymphocytes is about 90%, and excessive chemotherapy will shorten the survival time of patients; some tumors are not sensitive to drugs, and chemotherapy has no clinical value. However, the tumor did not disappear, and the tumor grew rapidly, and there were extensive near and distant metastases at the same time, which accelerated the metastasis of cancer cells while treating cancer, and also destroyed the immune system, so that some patients did not die of cancer, but died of cancer. Complications after overtreatment

Although there are different antigen types and combinations used to treat various diseases, since most of the cells in the tumor come from the human body itself, a single tumor antigen information is likely to cause immune escape of tumor cells, and the resulting immune response cannot successfully cause tumor damage. Kills, limited healing

In addition, because many tumor cells can secrete a variety of cytokines that inhibit the maturation of dendritic cells in the body, the number of dendritic cells present in the tumor site is relatively small, and the dendritic cells that are strongly stimulated by tumor antigens lack the anti-inflammatory effect induced by dendritic cells. The immune response of the tumor cannot play a very significant therapeutic effect in the host

Images